search icon

    Market Snapshot

    • S&P Futures

      3,819

    • Dow Futures

      30,822

    • Nasdaq Futures

      11,785

    blog search icon

    ALX Oncology Holdings Inc.

    (NASDAQ:ALXO)

    $9.41

    $0.26

    2.84%

    ALX Oncology Holdings Inc. Chart

    ALXO Stock Price Today

    ALX Oncology Holdings Inc. (ALXO) stock rallied over 2.84% intraday to trade at $9.41 a share on NASDAQ. The stock opened with a gain of 16.60% at $9.13 and touched an intraday high of $9.47, rising 2.84% against the last close of $9.15. The stock went to a low of $9.021 during the session.

    Stock Snapshot

    $9.15

    Prev. Close

    376.31 Million

    Market Cap

    $9.021

    Day Low

    $9.13

    Open

    40.62 Million

    Number of Shares

    $9.47

    Day High

    -

    P/E ratio

    -2.32

    EPS (TTM)

    8.95

    Cash Flow per Share

    18.18

    Free Float in %

    9.51

    Book Value

    252,759

    Volume

    ALX Oncology Holdings Inc. Historical Data

    DateOpenHighLowCloseVolume
    2022-07-06$9.13$9.47$9.021$9.41256,329
    2022-07-05$8.07$9.17$7.99$9.15320,500
    2022-07-01$8.07$8.31$8.05$8.23197,100
    2022-06-30$8.06$8.19$7.81$8.09229,700
    2022-06-29$8.12$8.225$7.72$8.1338,700
    2022-06-28$8.17$8.286$7.84$8.06288,000
    2022-06-27$7.89$8.31$7.55$8.18331,400
    2022-06-24$7.55$8.11$7.26$81,944,100
    2022-06-23$6.85$7.45$6.85$7.45202,900
    2022-06-22$6.56$7.16$6.56$6.79426,700

    Contact Details

    323 Allerton Avenue
    South San Francisco, CA 94080
    United States

    Webiste:ALXO

    650 466 7125

    Company Information

    Employees-

    Beta-

    Sales or Revenue0

    5Y Sales Change-

    Fiscal Year Ends2021-12-30

    SectorHealth Care

    IndustryBiotechnology

    About Company

    ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.

    Frequently Asked Questions

    icon

    What is the current ALX Oncology Holdings Inc. (ALXO) stock price?

    ALX Oncology Holdings Inc. (NASDAQ: ALXO) stock price is $9.41 as of the last check on Wednesday, July 6. During the trading session, ALXO stock reached the peak price of $9.47 while $9.021 was the lowest point it dropped to.

    icon

    ALXO's industry and sector of operation?

    The NASDAQ listed ALXO is part of Biotechnology industry that operates in the broader Health Care sector. ALX Oncology Holdings Inc. , a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer.

    icon

    Who are the executives of ALXO?

    Dr. Jaume Pons Ph.D.
    Pres, CEO & Director
    Dr. Michael Warner J.D., Ph.D.
    Gen. Counsel
    Dr. Corey S. Goodman Ph.D.
    Independent Exec. Chairman
    Dr. Jaume Pons Ph.D.
    Founder, Pres, CEO & Director

    icon

    What is the ALXO stock price today?

    ALXO stock traded closed the last session at $9.41, which is $0.26 or 2.84% lower than its previous close of $9.15. ALXO's current trading price is 61.68% lower than its 52-week high of $81.19 where as its distance from 52-week low of 5.82% is -88.41%.

    icon

    How many employees does ALXO have?

    Number of ALXO employees currently stands at -. ALXO operates from 323 Allerton Avenue, South San Francisco, CA 94080, United States.

    icon

    Link for ALXO official website?

    Official Webiste of $ALXO is: https://www.alxoncology.com

    icon

    How do I contact ALXO?

    ALXO could be contacted at ALXO operates from 323 Allerton Avenue, South San Francisco, CA 94080, United States, or at phone #650 466 7125 and can also be accessed through its website.

    icon

    How many shares of ALXO are traded daily?

    ALXO stock volume for the day was 252,759 shares while in the previous session number of ALXO shares traded was 256,329 . The average number of ALXO shares traded daily for last 3 months was 480.63 Thousands.

    icon

    How much did ALXO change today?

    The percentage change in ALXO stock occurred in the recent session was 2.84% while the dollar amount for the price change in ALXO stock was $0.26.

    icon

    What price range ALXO stock been trading in?

    In the recent session, the day high for ALXO stock was $9.47 while the low for ALXO stock touched on the day was $9.021.

    icon

    What is the market cap of ALXO currently?

    The market value of ALXO currently stands at 376.31 Million with its latest stock price at $9.41 and 40.62 Million of its shares outstanding.